trending Market Intelligence /marketintelligence/en/news-insights/trending/hWfG-vDvoUj-qITl4jwNSA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: BioNTech IPO could fetch up to $800M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Report: BioNTech IPO could fetch up to $800M

German biopharmaceutical company BioNTech AG has hired banks for a potential IPO that could raise up to $800 million, Reuters reported March 12, citing people familiar with the matter.

BioNTech develops individualized therapies for cancer and other diseases. The company's research platforms involve messenger Ribonucleic acid-based medicines, cell and gene therapies as well as protein therapies. The German company has partnerships with pharmaceutical giants including Roche Holding AG, Eli Lilly and Co., Pfizer Inc. and Sanofi.

Reuters reported that Bank of America and JP Morgan have been hired as global coordinators for the potential Nasdaq IPO.

The IPO could occur in the fourth quarter or early in 2020.

BioNTech, which raised about $270 million in a series A financing led by Redmile Group in January 2018, could be valued at about $4 billion, according to the report.